CureLab Receives $3M from Prominent Biotech Investor Dr. John Ballantyne
March 3, 2023
CureLab seeks new strategic partners to bring cancer innovation to market
September 29, 2023CureLab Oncology Secures Patent Protection for P62 Plasmid Therapeutic in India
BOSTON – July 13, 2023: CureLab Oncology, a clinical-stage biotech company, has been granted a patent in India for the treatment of non-cancerous diseases of chronic inflammation with its lead product, the DNA plasmid coding p62/SQSTM1 gene (p62). Chronic inflammation is an underlying condition that manifests itself in different organs and tissues as a multitude of diseases.
CureLab’s research has been focused on a new strategy for treatment of various diseases that involve chronic inflammation in their pathogenesis. CureLab’s lead product, Elenagen™, reduces chronic inflammation. In its ongoing cancer clinical studies, CureLab has observed a desirable safety profile and statistically significant evidence of clinical benefits of Elenagen for cancer patients.
With a population of 1.43 billion, India is the second most populous country in the world. However, India’s population is projected to continue growing and may become the world’s most populous country by 2027. Common inflammatory diseases in India include rheumatoid arthritis, Type 1 diabetes, chronic inflammatory demyelinating polyneuropathy, systemic lupus erythematosus, inflammatory bowel disease, psoriasis, Graves’ disease, and Hashimoto’s thyroiditis.
CureLab’s lead investigational compound is code-named Elenagen, an experimental DNA therapy that consists of a circular piece of DNA called a plasmid that includes a gene for a human protein called p62/SQSTM1. In clinical studies conducted ex-US, Elenagen demonstrated desirable safety profile and statistically significant clinical benefit for cancer patients enhancing the anti-cancer effects of chemotherapy. Experimental results also indicate mitigation of chronic inflammation, anti-aging effects, and stimulation of an immune response to the tumor. .
CureLab Oncology Inc. is a pre-IPO, clinical-stage biotech company headquartered in the greater Boston area, Massachusetts. CureLab is dedicated to advancing new and safer therapeutics for solid tumors and other oncology and inflammatory indications. To learn more, visit curelab.com.
Tim Cox, ZingPR, tim@zingpr.com
